Qué está moviendo el mercado.

X4 Pharmaceuticals secures up to $150M debt facility

X4 Pharmaceuticals (XFOR [https://seekingalpha.com/symbol/XFOR]) said [https://seekingalpha.com/pr/20679244-x4-pharmaceuticals-secures-up-to-150-million-senior-debt-facility-with-k2-healthventures]it entered into a senior secured term loan…

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

X4 Pharmaceuticals BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on August 31, 2026, the comp…

X4 Pharmaceuticals (XFOR) Reports Q2 Loss, Beats Revenue Estimates

X4 Pharmaceuticals (XFOR) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $3.47 per share a year ago. These figures are adjusted for non-recurring items.…

Sarepta Therapeutics (SRPT) Q2 Earnings and Revenues Surpass Estimates

Sarepta Therapeutics (SRPT) came out with quarterly earnings of $0.64 per share, beating the Zacks Consensus Estimate of $0.58 per share. This compares to earnings of $2.02 per share a year ago. These figures are adjusted for non-recurring…

X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors

BOSTON, July 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced the appointment of Kelly Gold to the Company’s Board of Director…

Here is Why X4 Pharmaceuticals (XFOR) is Among the Unrivaled Penny Stocks to Buy Now

With a stock price of $4.41, X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) is among the 10 Unrivaled Penny Stocks to Buy Now. X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) reported first-quarter revenue of $2.71 million on May 6, compared with analyst c…

X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Lags Revenue Estimates

X4 Pharmaceuticals (XFOR) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to earnings of $0.04 per share a year ago. These figures are adjusted for non-recurring items.…

Small-cap healthcare stocks with A+ grade EPS revisions ahead of earnings

[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images As Q1 2026 earnings season approaches, the healthcare sector enters reporting season as one of the market's primary l…

X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention

Quick Read X4 Pharmaceuticals (XFOR) at $3.97, target $12, raised $240.3M; Immuneering (IMRX) at $5.48, target $12; Tango Therapeutics (TNGX) at $16.60, target $24, up 87.25% YTD, 43.89% past week. X4 Pharmaceuticals, Immuneering, and Tang…

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on February 27, 2026, the company issued induce…

X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome

- Potential First and Only Therapy in the EU for Ultra-Rare Immune Disorder - BOSTON, Feb. 27, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, to…

Vericel Corporation (VCEL) Matches Q4 Earnings Estimates

Vericel Corporation (VCEL) came out with quarterly earnings of $0.45 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.38 per share a year ago. These figures are adjusted for non-recurring items. This q…

X4 Pharmaceuticals to Participate in Guggenheim’s Second Annual Healthcare Innovation Conference

BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare hematology diseases, today announced that the management team will participate in the upcoming Guggenhei…

X4 Pharmaceuticals (XFOR) Reports Q3 Loss, Misses Revenue Estimates

X4 Pharmaceuticals (XFOR) came out with a quarterly loss of $0.69 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to a loss of $5.41 per share a year ago. These figures are adjusted for non-recurring items.…

Techne (TECH) Meets Q1 Earnings Estimates

Techne (TECH) came out with quarterly earnings of $0.42 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.42 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it w…

Tuesday 10/28 Insider Buying Report: CRMD, XFOR

As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys. On Thursday, CorMedix's Director, Myron Kapla…

Healthcare Rally: Pulmonx, UHS, And X4 Lead After-Hours Gains Amid Strategic Updates

(RTTNews) - Several healthcare and biotech stocks posted notable gains in after-hours trading on Monday, driven by earnings updates, executive appointments, and capital market activity. Pulmonx Corp. (LUNG) surged 33.33% to $2.08 as of 9:3…

X4 Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $155.3 Million

BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR) (“X4” or the “Company”), a company driven to improve the lives of people with rare hematology diseases, today announced the closing of its previously announced und…

X4 Pharmaceuticals drops 5%, prices $135M equity

* X4 Pharmaceuticals (NASDAQ:XFOR [https://seekingalpha.com/symbol/XFOR]) priced [https://seekingalpha.com/pr/20278619-x4-pharmaceuticals-announces-pricing-of-135-million-underwritten-public-offering] its previously announced underwritten…

X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering

BOSTON, Oct. 24, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR) (“X4” or the “Company”), a company driven to improve the lives of people with rare hematology diseases, today announced the pricing of its previously announced und…

X4 Pharmaceuticals Announces Proposed Underwritten Public Offering

BOSTON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR) (“X4” or the “Company”), a company driven to improve the lives of people with rare hematology diseases, today announced that it has commenced an underwritten publi…

Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide

Seasoned clinical leader to oversee Phase 3 development of pemvidutide in MASH Dr. Arbet-Engels has led late-stage development, regulatory approvals and commercial launches for multiple successful franchises GAITHERSBURG, Md., Sept. 29, 20…

X4 Pharmaceuticals Restructures As CMO Resigns; 50% Workforce Cut Targets $13 Mln Savings

(RTTNews) - X4 Pharmaceuticals, Inc. (XFOR), on Wednesday, announced that Chief Medical Officer Christophe Arbet-Engels has resigned for personal reasons and Chief Operating Officer Mary DiBiase will leave the company. The company has appo…

X4 Pharmaceuticals to reduce 50% of workforce

* X4 Pharmaceuticals (NASDAQ:XFOR [https://seekingalpha.com/symbol/XFOR]) has announced a restructuring program to align resources with its long-term strategy to complete the Phase 3 4WARD trial for chronic neutropenia. * The plan includes…

X4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation

Organizational restructuring including a 50% reduction in workforce that is anticipated to result in annualized cost savings of approximately $13M John Volpone appointed Chief Operating Officer, in addition to his current role as President…

X4 Pharmaceuticals files to sell 59.89M shares of common stock for holders

* X4 Pharmaceuticals (NASDAQ:XFOR [https://seekingalpha.com/symbol/XFOR]) filed to sell 59.89M shares of common stock for holders. * Filing [https://seekingalpha.com/filing/10405571] MORE ON X4 PHARMACEUTICALS * Seeking Alpha’s Quant Ratin…

Sitryx appoints Adam Mostafa as Chief Financial Officer

Sitryx appoints Adam Mostafa as Chief Financial Officer Adam joins Sitryx with deep expertise in biotechnology capital markets, M&A and business development and strategic leadership Oxford, UK and Boston, MA – 8 September 2025 – Sitryx The…

Which stocks are experiencing notable movement on Tuesday?

Stay up-to-date with the latest market trends one hour before the close of the markets on Tuesday. Explore the top gainers and losers during today's session in our detailed report. [topmovers] GAINERS TICKER CHANGE COMMENT LASE [https://ww…

Curious about the stocks that are showing activity after the closing bell on Monday?

The US market regular session of Monday is over, let's have a look at the top gainers and losers in the after hours session today. [postmarket] AFTER HOURS GAINERS TICKER CHANGE COMMENT LASE [https://www.chartmill.com/stock/quote/LASE/prof…

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Aug. 15, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on August 12, 2025, the company issued in…

Unusual volume stocks are being observed in Wednesday's session.

Which stocks have an unusual volume on Wednesday? [unusualvolume] TOP UNUSUAL VOLUME STOCKS TICKER CHANGE COMMENT ADN [https://www.chartmill.com/stock/quote/ADN/profile] 4.49% ADVENT TECHNOLOGIES HOLDINGS'S (NASDAQ:ADN [https://www.chartmi…

BC-Most Active Stocks

NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks: Stock Name Volume High Low Last Change Momentus Inc. 164,681,829 2.33 1.69 1.73 +0.62 Wang & Lee Group Inc. 82,78…

Form 8K X4 Pharmaceuticals Inc For: 13 August

X4 Pharmaceuticals Announces Closing of Upsized $85 Million Private Placement

BOSTON, Aug. 13, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today closed an upsized private placement of 11,040,776 shares of common…

Top movers in Tuesday's session

Looking for insights into the US markets in the middle of the day on Tuesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. [topmovers] TODAY'S TOP GAINERS TICKER CHANGE COMMENT ATNF [https…

Let's uncover which stocks are experiencing notable gaps during today's session.

The market is filled with gapping stocks in Tuesday's session. Let's discover which stocks are showing gap-ups and gap-downs. [gap] TODAY'S GAP UP STOCKS TICKER CHANGE COMMENT ATNFW [https://www.chartmill.com/stock/quote/ATNFW/profile] 103…